Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

Lymphocyte-activation gene-3 (LAG-3), an immune checkpoint receptor, negatively regulates T-cell function and facilitates immune escape of tumors. Dual inhibition of LAG-3 and programmed cell death receptor-1 (PD-1) significantly improved progression-free survival (PFS) in metastatic melanoma patien...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2023-12-01
coleção:	OncoImmunology
Assuntos:	LAG-3 biomarker immune checkpoint inhibitors immunotherapy melanoma
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/2162402X.2023.2261248
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!